The safety profile of Yasmin is similar to other combined oral contraceptives

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 2, 2008, Pages 245-246

  Cronin, Maureen ^a   Korner, Paul ^b  

^a BAYER PHARMA AG   (Germany)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

DRUG SAFETY; HEART INFARCTION; HUMAN; LETTER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANDROSTENES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PROGESTERONE CONGENERS;

EID: 40549090883     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607310219     Document Type: Letter

References (4)

1. Orti G., Mira Y., Vaya A. Acute myocardial infarction associated with Yasmin oral contraceptive. Clin Appl Thromb Hemost. 2007 ; 13: 336-337.
2. Spitzer WO, Faith JM, MacRae KD Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod. 2002 ; 17: 2307-2314.
3. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007 ; 75: 344-354.
4. Seeger JD, Loughlin J., Eng PM, Clifford CR, Foegh M., Walker A. Venous thromboembolism among women using ethinyl estradiol with drospirenone and other oral contraceptives. Obstet Gynecol. 2007 ; 109 (suppl): 59S - 60S.